ArticleHuman vaccines & immunotherapeutics2025
Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy and safety of adding immune checkpoint inhibitors (ICIs) to neoadjuvant chemotherapy in patients with potentially resectable gastric cancer (GC) are uncertain. This study aimed to retrospectively evaluate the efficacy and safety of neoadjuvant ICIs plus chemotherapy in patients with potentially resectable GC. We retrospectively collected clinical data from patients with potentially resectable GC who received neoadjuvant treatment followed by gastrectomy at the Affiliated Hospital of Qingdao University from 2021 to 2023. The primary aim of this study was to investigate the differences in pathological tumor response (tumor regression grade, TRG) between neoadjuvant programmed cell death-(ligand)1 [PD-(L)1] blockade plus chemotherapy [neoadjuvant immunotherapy (IO) group] and chemotherapy alone (neoadjuvant chemotherapy group). Event-free survival (EFS) and treatment-related adverse events (TRAEs) were also observed. A total of 220 patients were retrospectively included in the analysis, among whom 96 (43.6%) received PD-(L)1 blockade plus chemotherapy as neoadjuvant treatment, and 124 (56.4%) received neoadjuvant chemotherapy. Higher pathological complete response (pCR) rate (21 of 96, 21.9% vs. 9 of 124, 7.2%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.